Guselkumab vs. Golimumab bei PsA-TNF-Patienten mit unzureichendem Ansprechen (EVOLUTION)
Guselkumab vs. Golimumab bei PsA-TNF-Patienten mit unzureichendem Ansprechen: eine pragmatische Studie (EVOLUTION)
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The primary aim of the trial will be to determine, among psoriatic arthritis (PsA) patients with an inadequate response (IR) to a tumor necrosis factor inhibitor (TNFi), whether switching to a new mechanism of action (MOA), specifically guselkumab (GUS), a selective interleukin 23 inhibitor (IL23i) targeting the p19 subunit, is more effective than switching to another TNFi. The primary hypothesis of this study is that switching to a new MOA may be more effective than switching to a second TNFi. This will be the first trial to test such a switch in PsA patients. Additionally, the proposed study will address the effectiveness of a new therapy, GUS, in a clinical practice setting among patients who are TNF IR.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Florida
-
Loxahatchee Groves, Florida, Vereinigte Staaten, 33470
- Family Arthritis Center
-
Plant City, Florida, Vereinigte Staaten, 33563
- Healing Rheumatology
-
Riverview, Florida, Vereinigte Staaten, 33569
- Southwest Florida Rheumatology
-
-
Georgia
-
Lilburn, Georgia, Vereinigte Staaten, 30047
- Parris and Associates
-
-
Massachusetts
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- University of Massachusetts Chan Medical School
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- University of Nebraska Medical Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10016
- New York University
-
-
Ohio
-
Blue Ash, Ohio, Vereinigte Staaten, 45242
- Cincy Arthritis
-
Wheelersburg, Ohio, Vereinigte Staaten, 45694
- Southern Ohio Rheumatology
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Hospital at the University of Pennsylvania
-
-
Tennessee
-
Crossville, Tennessee, Vereinigte Staaten, 38555
- Cumberland Rheumatology
-
-
Texas
-
Colleyville, Texas, Vereinigte Staaten, 76034
- Heritage Rheumatology and Arthritis Care
-
El Paso, Texas, Vereinigte Staaten, 79902
- Texas Arthritis Center
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84132
- University of Utah
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Psoriatic arthritis meeting CASPAR criteria;
- Active psoriatic arthritis defined by at least 1 swollen joint;
- cDAPSA score ≥ 10; See also Exclusion #4 - cDAPSA must be > 14 in patients without psoriasis.
- Using a TNFi or previously used a single TNFi historically and either never responded or lost response (TNF IR) and planning to switch to a new biologic therapy;
- If using an oral small molecule/csDMARD (i.e., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, or apremilast), must be on a stable dose for 4 weeks and remain on a stable dose during the study; Use of up to two OSM/csDMARDs is allowed.
- If using NSAIDs, glucocorticoids (<10 mg daily) or topical medications for psoriasis, must be on a stable dose for 4 weeks prior to Screening/Baseline 1 and remain on a stable dose during the study;
- Age 18-80 (patients older than 80 may be more likely to have concomitant osteoarthritis which may make it difficult to assess whether symptoms are related to PsA vs OA).
Exclusion Criteria:
-
Prior exposure to golimumab or another non-TNFi biologic (IL12/23i, JAKi, an IL17i, or an IL23i); prior exposure to a TYK2i is acceptable, but cannot be used during course of the study;
-
An adverse event that precludes use of another TNFi (development of drug-induced SLE, allergic reaction, serious infection, heart failure symptoms, demyelination at any point during use of therapy) or any other contraindication or substantial intolerance to a TNFi;
-
Use of moderate to high dose glucocorticoids (>10 mg);
-
Already meets the primary endpoint at Baseline; [cDAPSA low disease activity ≤ 14; IGA of psoriasis 0/1] In patients with psoriasis, cDAPSA can be 10-14 IF the Investigator Global Assessment of Psoriasis ≥ 2.
In patients without psoriasis, cDAPSA must be > 14 to meet eligibility requirements.
-
Currently pregnant or actively trying to conceive.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Guselkumab 100mg q4w
Guselkumab (GUS) 100mg every 4 weeks |
Guselkumab (GUS) subcutaneous injection
Andere Namen:
|
|
Experimental: Guselkumab 100mg q8w
Guselkumab (GUS) 100mg every 8 weeks |
Guselkumab (GUS) subcutaneous injection
Andere Namen:
|
|
Aktiver Komparator: Golimumab 50mg q4w
Golimumab (GOL) 50mg every 4 weeks |
Golimumab (GOL) subcutaneous injection
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Achievement of cDAPSA low disease activity
Zeitfenster: 12 Months
|
Clinical Disease Activity in Psoriatic Arthritis (cDAPSA): a combination score of tender joint count, swollen joint count, patient assessment of pain, and patient global assessment of disease activity. Scale from 0-154 where higher figures indicate worse status. Remission is considered ≤4 and low disease activity >4 to ≤13. |
12 Months
|
|
Investigator Global Assessment of Psoriasis of Clear or Almost Clear
Zeitfenster: 12 Months
|
Investigator global assessment (IGA) of psoriasis. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). |
12 Months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Minimal Disease Activity (MDA) using PSAID-12
Zeitfenster: 6 and 12 months
|
Minimal Disease Activity (MDA) defines a satisfactory state of disease activity that includes 5 domains of PsA. 5/7 of the following criteria must be satisfied for MDA: patient global ≤ 2 (0-10), patient pain ≤ 2 (0-10), PSAID-12 <4 (0-10), TJC (Tender Joint Count) ≤ 1, SJC (Swollen Joint Count) ≤ 1, BSA (Body Surface Area) ≤ 3, and Leeds Enthesitis Index ≤ 1. |
6 and 12 months
|
|
Minimal Disease Activity (MDA) using HAQ-DI
Zeitfenster: 6 and 12 months
|
(MDA) Minimal Disease Activity defines a satisfactory state of disease activity that includes 5 domains of PsA. Participant would need to achieve 5/7 of the following criteria: patient global ≤ 2 (0-10), patient pain ≤ 2 (0-10), HAQ-DI (Health Assessment Questionnaire Disability Index) < 0.5 (0-3), TJC (Tender Joint Count) ≤ 1, SJC (Swollen Joint Count) ≤ 1, BSA (Body Surface Area) ≤ 3, and Leeds Enthesitis Index ≤ 1. |
6 and 12 months
|
|
Change in PSAID-12
Zeitfenster: 6 and 12 months
|
Psoriatic Arthritis Impact of Disease Questionnaire 12-item questionnaire (PSAID-12) Survey. The range of the final PsAID-12 value is 0-10 where higher figures indicate worse status. Negative changes from baseline indicate improvement in disease activity. |
6 and 12 months
|
|
PSAID-12 < 4
Zeitfenster: 6 and 12 months
|
Psoriatic Arthritis Impact of Disease Questionnaire 12-item questionnaire (PSAID-12) Survey. The range of the final PsAID-12 value is 0-10 where higher figures indicate worse status. |
6 and 12 months
|
|
Change in DLQI
Zeitfenster: 6 and 12 months
|
Dermatology Life Quality Index (DLQI) is a measure of skin disease activity. Calculated score of 0-30 where higher figures indicate worse status.Negative changes from baseline indicate improvement in disease activity. |
6 and 12 months
|
|
IGA Among Patients with BSA > 3% at Baseline
Zeitfenster: 6 and 12 months
|
Investigator global assessment (IGA) of psoriasis among patients with BSA (Body Surface Area) >3% at baseline. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). |
6 and 12 months
|
|
IGA Among Patients with IGA ≥ 2 at Baseline
Zeitfenster: 6 and 12 months
|
Investigator global assessment (IGA) of psoriasis among patients with IGA of 2 or more (≥ 2) at baseline. A scale of 0-4 where higher figures indicate worse status. (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). |
6 and 12 months
|
|
Change in Promis Fatigue
Zeitfenster: 6 and 12 Months
|
Promis Fatigue is a measure of fatigue with a score from 8-40 where higher figures indicate worse status. A negative change indicates less overall fatigue. |
6 and 12 Months
|
|
Resolution of Dactylitis
Zeitfenster: 6 and 12 Months
|
Dactylitis is assessed using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. These results are summed to produce a final score ranging from 0 to 20. A higher score indicates more severe dactylitis. Resolution of dactylitis is defined as a dactylitis score of 0 with a baseline dactylitis score >0. |
6 and 12 Months
|
|
Resolution of Enthesitis
Zeitfenster: 6 and 12 Months
|
Enthesitis is assessed using the Leeds Enthesitis Index (LEI). This measure includes the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The total LEI score of 0-6 is based on evaluating each of these six sites as 0 or 1 based on the absence or presence of pain/tenderness. Resolution of enthesitis is defined as a enthesitis score of 0 with a baseline enthesitis score >0. |
6 and 12 Months
|
|
Change in BASDAI
Zeitfenster: 6 and 12 Months
|
Change in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) among patients with axial disease. The BASDAI sum score ranges from 0 to 10 and higher values indicate more active disease. Negative changes from baseline indicate improvement in disease activity. |
6 and 12 Months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Alexis Ogdie-Beatty, MD, MSCE, University of Pennsylvania
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Knochenerkrankungen
- Erkrankungen des Bewegungsapparates
- Arthritis
- Gelenkerkrankungen
- Erkrankungen der Wirbelsäule
- Spondylarthropathien
- Hautkrankheiten, papulosquamös
- Hautkrankheiten
- Spondylarthritis
- Spondylitis
- Schuppenflechte
- Haut- und Bindegewebserkrankungen
- Arthritis, Psoriasis
- Guselkumab
- Golimumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CNTO1959PSA3006
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .